Home>Topics>Industry>Biotechnology Industry

Biotechnology Industry

  1. All
  2. Stock Reports
  1. New Morningstar Analyst Report - Anheuser-Busch InBev SA

    Stock Reports

    Tue, 22 May 2012

    After successfully integrating Budweiser, ABInBev is concentrating on driving the business forward.

  2. New Morningstar Analyst Report - MannKind Corporation

    Stock Reports

    Mon, 14 May 2012

    MannKind received another complete response letter for Afrezza. With a rising debt load and only early-stage drugs remaining in its pipeline, shareholders are likely to be left empty-handed if MannKind is unable to meet agency demands.Even if Afrezza succeeds in gaining approval, the product could

  3. New Morningstar Analyst Report - Gilead Sciences

    Stock Reports

    Mon, 14 May 2012

    Gilead's HIV portfolio gains longevity with the quad, and its hepatitis C pipeline brings growth.

  4. New Morningstar Analyst Report for Savient Pharmaceuticals

    Stock Reports

    Fri, 11 May 2012

    Despite numerous setbacks and poor execution, Savient still has a strong product.

  5. New Morningstar Analyst Report - Shire PLC

    Stock Reports

    Fri, 11 May 2012

    Prior to the arrival of generic competition, Adderall XR sales represented 36% of Shire's revenue in 2008. The entrance of generics in 2009 has put significant pressure on the rest of Shire's pipeline to perform.Sanofi's shortages of core rare disease therapeutics Cerezyme and Fabrazyme appear to

  6. New Morningstar Analyst Report - Celgene

    Stock Reports

    Fri, 11 May 2012

    Revlimid use is poised to expand at double-digit rates over the next several years.

  7. New Morningstar Analyst Report for Biogen Idec Inc

    Stock Reports

    Wed, 9 May 2012

    Biogen's late-stage pipeline--in MS and beyond--is rapidly approaching the market.

  8. New Morningstar Analyst Report - Amgen

    Stock Reports

    Wed, 9 May 2012

    Amgen's improving pipeline could effectively counter new competitive threats.

  9. New Morningstar Analyst Report - Vanda Pharmaceuticals, Inc.

    Stock Reports

    Tue, 8 May 2012

    Vanda is trading below cash levels, but we see value in its commercial and experimental therapies.

  10. New Morningstar Analyst Report - Exelixis, Inc.

    Stock Reports

    Fri, 4 May 2012

    Exelixis' lead drug cabozantinib could see approval in multiple indications.

« Prev12345Next »
Content Partners